Ixekizumab confers efficacy for up to 4 years in moderate-to-severe psoriasis
It appears that the efficacy of ixekizumab treatment in patients with moderate-to-severe psoriasis lasts for up to 4 years, according to a phase II study.
The investigators performed analysis by last observation carried forward involving patients who received ixekizumab 120 mg and then 80 mg subcutaneously once every 4 weeks.
Ninety-three percent of the patients who completed the randomized placebo-controlled trial entered the open-label extension (OLE). There was a 75-percent decrease in the Psoriasis Area Severity Index score in 82 percent of patients at week 208 of the OLE.
Sixty-four percent of patients had a static Physician Global Assessment score of 0 or 1, and 45 percent had a score of 0 at week 208. Compared with baseline, a decrease was observed in the patients’ Dermatology Life Quality Index and Itch visual analogue scale scores. There were also improvements in other efficacy and health outcome measures.
Serious adverse events (AE) were reported in 16.7 percent of patients, and 87 percent had one or more treatment-emergent AE. Serious infections occurred in three patients, while one patient reported two major cardiovascular events.
This study was limited by the lack of a placebo or active comparator, and it was also unblinded.
A previous phase III trial (UNCOVER-3) has found that ixekizumab is well tolerated and yields persistent efficacy through 108 weeks. [J Am Acad Dermatol 2017;77:855-862]
“Ixekizumab has demonstrated improvement in patients with moderate-to-severe psoriasis by selectively targeting interleukin-17A, which is a proinflammatory cytokine that is important in the pathogenesis of psoriasis,” the investigators said.